Insmed Q3 revenue $67.7M (+45% YoY); net loss $1.09/share; secures $775M financing

INSMED Inc

2022-Q3 EPS reported -$2.68 revenue$186,058,000

ARIKAYCE total revenue of $67.7M: $49.5M U.S., $14.5M Japan, $3.7M Europe/RoW.
Net loss of $131.1M ($1.09 per share) vs $112.7M ($0.96) in Q3 2021.
Cash and marketable securities $513.3M; strategic financings added $775M gross proceeds.
Full-year 2022 ARIKAYCE revenue expected to grow at least 30% YoY.
Phase 3 ASPEN (brensocatib) enrollment on track; topline data expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSMED Inc reported full-year 2022 results: revenue at least 30% year over year. Guidance reaffirmed.

Period: full-year 2022
Revenue: at least 30% year over year
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Insmed continues to expect full-year 2022 global revenues for ARIKAYCE to increase at least 30% year over year from 2021

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INSMED Inc reported three months ended September 30, 2022 results: net income $131.1 million, EPS $1.09.

Period: three months ended September 30, 2022
Net income: $131.1 million
EPS: $1.09
Result: reported results

Exact text from the filing

Insmed reported a net loss of $131.1 million, or $1.09 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INSMED Inc reported three months and nine months ended September 30, 2022 results: revenue $67.7 million, net income $131.1 million, EPS $1.09. Guidance reaffirmed.

Period: three months and nine months ended September 30, 2022
Revenue: $67.7 million
Net income: $131.1 million
EPS: $1.09
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the third quarter ended September 30, 2022, was $67.7 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-22-038593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.